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bladder cancer according to depth of lamina
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patients
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MA 02215, USA; 2Departments of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard Medical School,
Boston, MA 02215, USA; 3Department of Pathology, Vall d’Hebron Hospital, Barcelona 08035, Spain; 4University of Massachusetts
Medical School, Worcester, MA 01655, USA; 5Department of Urology, Vall d’Hebron Hospital, Barcelona 08035, Spain; 6Center for
Surgery and Public Health, Brigham and Women’s Hospital, Boston, MA 02215, USA; 7Division of Urology, Brigham and Women’s
Hospital, Boston, MA 02215, USA and 8Department of Pathology, Dana-Farber/Brigham and Women’s Hospital Cancer Center,
Harvard Medical School, Boston, MA 02215, USA
Background: Management of high-grade T1 (HGT1) bladder cancer represents a major challenge. We studied a treatment
strategy according to substaging by depth of lamina propria invasion.
Methods: In this prospective observational cohort study, patients received initial transurethral resection (TUR), mitomycin-C, and
BCG. Subjects with shallower lamina propria invasion (HGT1a) were followed without further surgery, whereas subjects with
HGT1b received a second TUR. Association of clinical and histological features with outcomes (primary: progression; secondary:
recurrence and cancer-specific survival) was assessed using Cox regression.
Results: Median age was 71 years; 89.5% were males, with 89 (44.5%) cases T1a and 111 (55.5%) T1b. At median follow-up of
71months, disease progression was observed in 31 (15.5%) and in univariate analysis, substaging, carcinoma in situ, tumour size,
and tumour pattern predicted progression. On multivariate analysis only substaging, associated carcinoma in situ, and tumour size
remained significant for progression.
Conclusions: In HGT1 bladder cancer, the strategy of performing a second TUR only in T1b cases results in a global low
progression rate of 15.5%. Tumours deeply invading the lamina propria (HGT1b) showed a three-fold increase in risk of
progression. Substaging should be routinely evaluated, with HGT1b cases being thoroughly evaluated for cystectomy. Inclusion in
the TNM system should also be carefully considered.
Over 150 000 and 72 000 new cases of bladder cancer (BC) are
estimated to be diagnosed each year in Europe and the United States,
respectively (Ferlay et al, 2013). When initially diagnosed, most are
non-muscle invasive (NMIBC); that is, either non-invasive and
confined to the mucosa (Ta and carcinoma in situ (CIS)) or invading
the lamina propria (LP) but not yet the detrusor muscle (T1).
T1 of high cellular grade (HGT1), the subset of NMIBC with the
highest risk of progression, may exhibit histopathological, clinical,
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and biological characteristics of invasive tumours. Even though
classically 30% of these tumours have been considered to progress
(Sylvester et al, 2006), updated data show a 21% progression rate
(van den Bosch and Alfred Witjes, 2011). Therefore, a notable
proportion of HGT1 behave in a relatively indolent manner and up
to one-third resolve ad integrum after standard treatment
(Pansadoro et al, 2002; Jakse et al, 2004). This wide range of
tumour biology highlights the need to risk stratify these patients.
Unfortunately, for high-risk NMIBC, both EORTC and CUETO
scoring systems have poor discriminating ability and limited
predictive value, tending to overestimate progression (van den
Bosch and Alfred Witjes, 2011; Xylinas et al, 2013).
As a result, there is a need to reexamine management of HGT1
BC. Standard initial treatment is based on endoscopic transurethral
resection (TUR), and intravesical immunotherapy with BCG. A
repeat resection (reTUR) is recommended by guidelines to rule out
understaging (American Urological Association, 2007; Babjuk et al,
2013), even though for an array of reasons, reTUR remains
underutilised with no higher than 7.7% of HGT1 patients
reportedly undergoing this second procedure even at tertiary care
centres (Skolarus et al, 2011). ReTUR may improve outcome (Herr
et al, 2007) but adds morbidity and is probably unnecessary in over
60% of cases, while 6.5–30% might still progress (Divrik et al, 2010;
Sfakianos et al, 2014). Conversely, prolongation of conservative
treatment and deferring radical cystectomy may allow progression
and decrease cancer-specific survival (CSS) (Raj et al, 2007, Divrik
et al, 2010). Deciding upon ideal timing for cystectomy is one of
the most difficult clinical decisions in urology and an ongoing area
of controversy. This major surgical procedure requires urinary
diversion, is associated with substantial morbidity (50– 67%
complication rate) and up to 9% mortality (Aziz et al, 2013), and
may represent overtreatment (Pansadoro et al, 2002). Therefore,
identifying those cases of HGT1 suitable for organ preservation
and differentiating them from those that will most benefit from a
timely cystectomy is a major challenge and key to improving
outcomes.
Our group has been working to improve treatment strategy in
HGT1 BC and, with others, has shown that substaging HGT1
according to the depth of LP invasion allows identification of
patients at low (T1a) and high (T1b) risk of progression (Orsola
et al, 2005; Roupreˆt et al, 2013). Based on this evidence and to
optimise resources, we designed a strategy by which a second TUR
was indicated only in patients with deep LP invasion (T1b). In
addition, because BCG response is also a strong predictor of
progression, the second TUR was performed after a course of BCG
induction. In the preliminary report of this series (Orsola et al,
2010), we showed that tumour size 43 cm and associated CIS
predict positive findings in the first evaluation at 3 months and
speculated that HGT1a cases can safely forgo a second TUR.
In this study, we present the mature results of the first 200 cases
of initial HGT1 treated with this optimised approach, at 71months
median follow-up, assessing recurrence, progression, and CSS, as
well as evaluating clinical and histological features as prognostic
factors.
MATERIALS AND METHODS
Trial design and inclusion of this prospective observational cohort
study began in April 2005. Since then, patients diagnosed at initial
TUR with HGT1 BC were offered entry into this protocol.
Transurethral resection BT included complete resection of all
visible tumours, with a separate base biopsy. Cold cup biopsies to
detect CIS were taken, depending on surgeon preference,
in a standardised manner or according to EAU Guidelines
(abnormal urothelium, non-papillary tumour appearance, or
positive cytology) (Babjuk et al, 2013). All patients received a
postoperative dose of intravesical mitomycin-C.
Tumours were graded according to the 2004 WHO system
(2006) after pathological assessment of the total specimen. A two-
tier system (Cottrell et al, 2007) was used to assess the depth of LP
invasion: T1a when tumour involved the subepithelial connective
tissue superficial to muscularis mucosae (MM); T1b when tumour
was found at the level of or beyond MM. When MM was not
identifiable, thick-walled blood vessels deep in LP served as a
landmark, or alternatively location of MM in tumour-free tissue of
the same TUR was used for reference. Only initial HGT1 tumours
with a visible, clearly identifiable and disease-free muscularis
propria were included in this study. Patients with LP invasion (T1)
but without muscularis propria in the specimen represent B10%
of all T1 in our centre. These cases, identified as Tx, did not fulfill
the requirements to enter this protocol and, following guidelines,
directly underwent a repeat resection.
This protocol was approved by the Hospital Ethics Committee
and registered at clinicaltrials.gov (NCT02113501), and last
evaluation of patients was performed in February 2014. Enrolled
subjects received six weekly instillations of 2–8 108 UFC BCG-
Tice (OncoTICE, Schering-Plough Canada Inc., Kirkland, QC,
Canada) and, at 3 months after initial TUR, underwent either a
second TUR post-BCG (T1b) or a cystoscopy plus cytology (T1a).
Follow-up included BCG maintenance; the strategy is summarised
in Figure 1 and described in detail in our previous report (Orsola
et al, 2010). Baseline characteristics were compared between the
T1a and T1b groups using Fisher’s exact test.
The primary objective was the assessment of progression,
recurrence, and CSS. Progression was defined as occurrence of an
invasive tumour at post-BCG TUR, the development of muscle
invasive or more advanced stage carcinoma, distant metastasis, or
death from BC. Time to progression was defined as time from
diagnosis of BC to the date when disease progression was observed,
or censored on the last known date alive without progression.
Recurrence was defined as the first evidence of any NMIBC
detected on follow-up. Time to recurrence was defined as time
from diagnosis of BC to the date when disease recurrence was
observed, or censored at the last known date alive without disease
recurrence, or at date of progression. Cancer-specific survival was
defined as death from the same cancer or related causes.
HGT1 at TUR of initial BC
HG T1a HG T1b
BCG x 6BCG x 6 + maintenance
(36 m)
If nagative
Continue BCG
maintenance
If nagative
Continue BCG
maintenance
If positive
TUR (+/–BRB)
(continue protocol
according to risk level)
If positive
3rd TUR + BCG or
CYSTECTOMY*
2nd TUR (+/– BRB)
(1m after induction)
Cystoscopy + cytology at 3m
Figure 1. Summary of the protocol. For all patients with positive
findings at 3 months, the final decision about treatment, including the
option of cystectomy, was taken according to disease status and
the patient’s preference. Fourteen percent cases did not receive
immediate MitC post-TUR. BCG maintenance schedule consisted of
three weekly instillations of Oncotice at 3 months and every 6 months
thereafter (for 2–3 years depending on tolerance). *According to
physician advice and patients choice. Abbreviations: BRB¼bladder
random biopsies; TUR¼ trans urethral resection.
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The secondary objective was the assessment of prognostic
factors. Eleven clinical and pathological variables were prospec-
tively documented to evaluate their capacity to predict events.
Kaplan–Meier analysis was used to summarise median time to
recurrence and time to progression. Association of time to
recurrence, time to progression, and CSS with the variables of
interest was assessed using Cox regression models in univariate and
multivariable models, reporting hazard ratios (HRs) and 95% CI.
RESULTS
Two hundred primary urothelial HGT1 cases have been identified
at TUR and have entered the present protocol. Median age at
diagnosis was 71 years; 89.5% were males, with 89 (44.5%) cases
being T1a and 111 (55.5%) T1b. Patients and tumour character-
istics are shown in Table 1 classified by substaging. The median
follow-up period was 71 months (range: 5–107months). The
second TUR (performed only in T1b) was negative in 67.5% of
cases and positive in the remaining 32.4% (11 invasive and 25 non-
invasive; primary histology being persistent HGT1). Tolerance and
patient dropout of BCG was not documented specifically within
the study group, but for the broader population of high-risk BC at
our hospital B30% do not complete the first year.
Recurrence was observed in 57 (28.5%) patients and disease
progression in 31 (15.5%). In total, 46 patients died (13 of BC, 14
of other cancers, 18 of other causes, and one of unknown cause)
and 18 underwent cystectomy (2 pT0, 1 pT1, 4 pTIS, 3 pT2, 4 pT3,
and 3 pT4; one cystectomy at another centre; and 3 presented with
positive lymph nodes). Ten potential candidates for cystectomy
received palliative treatment because they were considered
ineligible due to high surgical and/or anaesthetic risk.
The association of relevant clinical and pathological variables
with time to progression and recurrence is presented in Table 2.
Median time to recurrence was not reached; 2- and 5-year
recurrence-free rates are summarised. Recurrence rate was not
significantly different among HGT1a (21 cases, 22%) and HGT1b
(36 cases, 34.6%), with only age at diagnosis remaining significant
on multivariate analysis. Table 3a and b summarise univariate and
multivariate analysis for recurrence.
Progression rate demonstrated a significant difference based on
substaging, with HGT1b tumours showing an increased risk of
progression (5 T1a (5.6%) vs 26 T1b (23.6%)). Median time to
progression was not reached; the 2- and 5-year progression-free
rates are summarised in Table 4a. Variables significant in
univariate analysis together with lymphovascular invasion (LVI)
and gender (significant in previous publications, but not in the
current univariate analysis) were evaluated in a multivariable
model for time to progression (Table 4b). Substaging, CIS, and
tumour size remained significant in this model. Figure 2 illustrates
the Kaplan–Meier curves for progression in relation to substaging,
tumour pattern, tumour size, and associated CIS.
The low number of deaths due to BC precluded analysis of
predictors of CSS. Five-year CSS was 99% for T1a and 95% for T1b.
Of the 13 patients who died due to BC (3 of local progression (no
cystectomy) and 10 from metastatic BC, 6 of which had undergone
cystectomy) all except one were originally T1b.
Finally, the association of TIS and tumour size in deeply
invasive cases (T1b) gave an HR for progression of 4.81 with 95%
CI (2.07, 11.20) (P¼ 0.0003) for patients with T1bþCISþ43 cm
compared with the rest.
DISCUSSION
In HGT1 BC, the proposed strategy of deferring a second TUR
until after induction of BCG and doing so only in T1b cases, results
in a global low progression rate of 15.5%. Cases in which tumours
invaded the MM (T1b) had a three-fold increased risk of
Table 1. Association of clinical and histological variables with
substaging (T1a vs T1b)
T1a T1b Total P
Age (years) (o70/X70) 44/45 52/59 96/104 0.78
Gender: Male/Female 79/10 100/11 179/21 0.82
Tumour size: o3 cm/43 cm 55/34 59/52 114/86 0.14
Tumour number: solitary/multiple 49/40 60/51 109/91 40.99
Tumour pattern: papillary/solid 84/5 82/29 166/34 0.0001
Lymphovascular invasion: yes/no 1/88 6/105 7/193 0.09
Micropapillarya: yes/no 3/86 12/99 15/185 0.06
Squamous metaplasia: yes/no 21/68 40/71 61/139 0.06
CISa: yes/no 17/72 40/71 57/143 0.01
CIS in prostateb: yes/no 0/79 7/93 7/172 0.02
Abbreviation: CIS¼ carcinoma in situ. Subjects with T1b disease presented with significantly
higher rates of solid pattern, associated bladder CIS and prostate CIS.
a133 Patients underwent random bladder biopsies.
bOnly evaluated in male patients.
Table 2. Univariate analysis for association of clinically and pathologically relevant variables with time to recurrence and time to
progression
Recurrence Progression
Hazard ratio (95% CI) P Hazard ratio (95% CI) P
Age (years) o70/X70 0.5 (0.29, 0.86) 0.01 0.59 (0.29, 1.22) 0.15
Gender: Male/Female 0.81 (0.37, 1.78) 0.59 1.09 (0.33, 3.59) 0.89
Tumour size: o3 cm/43 cm 0.59 (0.35, 0.99) 0.04 0.44 (0.22, 0.91) 0.02
Tumour number: solitary/multiple 0.68 (0.40, 1.14) 0.14 0.66 (0.33, 1.34) 0.25
Tumour pattern: papillary/solid 0.76 (0.39, 1.47) 0.41 0.37 (0.17, 0.78) 0.006
Lymphovascular invasion: yes/no 2.63 (0.95, 7.27) 0.06 3.11 (0.94, 10.28) 0.06
Micropapillary*: yes/no 0.69 (0.23, 2.21) 0.53 0.99 (0.24, 4.19) 0.99
Squamous metaplasia: yes/no 1.18 (0.68, 2.04) 0.57 1.00 (0.46, 2.17) 0.99
CIS: yes/no 0.71 (0.41, 1.25) 0.23 0.23 (0.46, 2.17) o0.0001
CIS in prostate: yes/no 0.84 (0.20, 3.44) 0.80 0.45 (0.11, 1.88) 0.26
Substaging: T1a/T1b 0.61 (0.36, 1.04) 0.07 0.21 (0.08, 0.54) 0.0004
Abbreviations: CI¼ confidence interval; CIS¼ carcinoma in situ. *Any % of micropapillary component. Po0.05 represent statistically significant values (shown in bold).
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progression compared with those without MM invasion (T1a),
even though the latter group was treated more conservatively.
Our report goes on to confirm the role of CIS, tumour size, and
tumour pattern as prognostic factors for worse outcomes in this
group of high-risk non-muscle invasive BC.
To the best of our knowledge, this is the first report addressing
the role of substaging HGT1 BC prospectively to guide therapeutic
management. This novel strategy, together with the relatively large
number of cases of initial HGT1, the long follow-up and the
consistent treatment approach are the main strengths of our series.
In addition, the evaluation of depth of tumour invasion was
performed prospectively after TUR as part of the routine
pathological report, whereas most reports on HGT1 are retro-
spective and observational. We cannot rule out bias due to patient
selection since cases with recurrent tumours and those with no
muscularis propria identified were not included; our series might
also include some G2 cases (WHO 1974 classification) under the
broader definition of HG BC. On the other hand, tumours that
could have been understaged (early progressors or positive second
TUR) were not excluded from the analysis in the understanding
that this represents a more generalisable real-world practice, but
might also be seen as a bias. Finally, our results are limited by the
fact that the study was performed in a non-randomised manner.
This limitation is widespread in the high-risk BC literature as most
reports have retrospective observational designs, with few rando-
mised studies (Martin-Doyle et al, 2014). Given the public nature
of our health-care system, we chose to differentially allocate
patients to treatment, using a more aggressive approach for T1b
tumours, aiming to optimise resources.
The role of substaging has been well established throughout the
past 20 years, with over 2500 published cases substaged according
to invasion of the MM (Roupreˆt et al, 2013). The relevance of this
factor has been recently confirmed in the largest meta-analysis ever
conducted on prognostic factors in HGT1 (Martin-Doyle et al,
2014). Because the evaluation of the depth of invasion is subject to
interobserver and intraobserver variability, this parameter has been
criticised for the last two decades, but there is growing evidence on
the reproducibility of this evaluation. In a study specifically
addressing this issue, Cottrell et al (2007) elegantly showed a high
concordance rate among general pathologists after guidance based
only in a presentation of the staging systems as described by the
SIGN guideline. In their report, the median K concordance rate was
0.623, which is higher than that attained for Gleason score among
pathologists (Bottke et al, 2013). In a more recent report, Roupreˆt
et al (2013) showed a reclassification rate for substaging of only 16%
after central review of 587 HGT1 BC tumour sets from a multicentre
data set. Other methods to substage HGT1 have been described
using either millimetric evaluation of the depth of invasion (Cheng
et al, 1999; Chang et al, 2012), measuring the size of the infiltrative
tumour area asp or4 1 high-power field (Cheng et al, 1999; Bertz
et al, 2011) or describing the extent of invasion (microinvasive or
extensive) (van der Aa et al, 2005; van Rhijn et al, 2012). These
alternative systems, however, have all been studied retrospectively in
single data sets of patients and have not yet been externally validated
(Martin-Doyle et al, 2014). A head-to-head comparison among
these approaches in a large data set unfortunately is unavailable to
date. Nonetheless, the fact that substaging remained a robust
prognostic factor in our series (three-fold increase risk of
progression in the adjusted multivariable model, and five-fold
increase in the univariate model), even though patients with HGT1a
underwent a more conservative approach demonstrates the
magnitude of negative impact associated with depth of invasion.
We report a 15.5% progression rate, which is lower than the
recently published pooled results ofB20% progression rate for this
high-risk group of tumours (van den Bosch and Alfred Witjes,
2011; Gontero et al, 2014; Martin-Doyle et al, 2014). Progression
rates for high-risk BC have typically been considered to be over
30% and up to 50%, but more current data support that
approximately one in five cases progress and will typically do so
within 48 months of initial diagnosis (van den Bosch and Alfred
Witjes, 2011). Our approach of proceeding with the second TUR
after the 6-week induction of BCG (Orsola et al, 2010) was also
used by Denzinger et al (2007) with an overall progression rate of
41% in 132 patients. We contend that the better outcome in our
series might be attributable to a complete, deep, and radical initial
TUR together with the exclusion of cases without clear muscularis
propria in the TURBT specimen. It is possible the use of BCG
(induction and maintenance) and the second TUR have also
contributed an added therapeutic benefit. The combined influence
of all these factors might explain the low rate of understaging we
found in the second TUR (9.9%) as well as the low rate of positive
findings at 3 months (Orsola et al, 2010), but the limitations
mentioned previously should also be taken into account.
Mitomycin-C might have only played a minor role given that no
impact on progression has been demonstrated with this agent in all
randomised published trials. Also the proposed approach in
delaying the second TUR makes it impossible to accurately
Table 3b. Multivariable analysis for recurrence; association of
CIS, substaging, tumour size, tumour pattern, lymphovascular
invasion and gender with time to recurrence
Hazard ratio and
95% CI P
Substaging (T1a) 0.64 (0.37, 1.14) 0.13
CIS (No) 0.68 (0.38, 1.21) 0.19
Size (o3 cm) 0.59 (0.34, 1.01) 0.06
Pattern (papillary) 1.12 (0.53, 2.37) 0.78
Lymphovascular invasion (yes) 2.16 (0.71, 6.59) 0.18
Gender (male) 0.81 (0.36, 1.81) 0.60
Age (o70 years) 0.50 (0.29, 0.87) 0.01
Abbreviations: CI¼ confidence interval; CIS¼ carcinoma in situ. Po0.05 represent
statistically significant values (shown in bold).
Table 3a. Univariate analysis for recurrence; association of tumour size and age at diagnosis with time to recurrence at 2 and 5
years (only showing variables with significant P-values)
N Recur
Recurrence free
at 2 years
Recurrence free
at 5 years
Hazard ratio and
95% CI P
Tumour size 0.04
o3 cm 113 27 0.81 (0.72, 0.87) 0.76 (0.67, 0.83) 0.59 (0.35, 0.99)
43 cm 86 30 0.72 (0.60, 0.80) 0.59 (0.46, 0.70) 1 (reference)
Age at dx 0.01
o70 96 20 0.85 (0.76, 0.91) 0.78 (0.67, 0.85) 0.50 (0.29, 0.86)
X70 103 37 0.70 (0.59, 0.78) 0.58 (0.47, 0.69) 1 (reference)
Abbreviation: CI¼ confidence interval. Po0.05 represent statistically significant values (shown in bold).
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differentiate between true understaging and early invasive
recurrence.
Our study goes on to corroborate previous observations that CIS
is a strong prognostic factor with a two-fold increase in risk of
progression (Sylvester et al, 2006). In our report, the impact was
even stronger with a 0.23 HR favouring lack of CIS. Interestingly,
we observed a high rate of detection in those patients who,
according to surgeon preference, underwent multiple random
bladder biopsies. This adds to the debate of whether routine
bladder biopsies, which we have previously defended (Orsola et al,
2010), should be standardised at the time of initial BC TUR
(Millan-Rodriguez et al, 2000). The usefulness of random bladder
biopsies in the broad population of NMIBC is controversial
(Kiemeney et al, 1994), but our findings suggest that a high positive
yield is obtained in HGT1 cases. Alternatively, the diagnosis of CIS
is based on its detection in either peritumoral areas of the specimen
or if suspicious areas are biopsied. This approach, currently
recommended by guidelines (American Urological Association,
2007; Babjuk et al, 2013), is highly limited by interpretation and
likely leads to underdetection of true CIS, even though fluores-
cence-guided TURBT might improve identification of suspicious
areas of CIS (Witjes et al, 2014). Finally, the findings of our study
suggest that larger tumours and those with a solid pattern are
associated with a worse outcome in HGT1, are consistent with the
relevance of these parameters in the broader NMIBC population.
Combining these factors we observed that patients with T1b
tumours that were larger than 3 cm and associated with CIS were
4.8 times more likely to progress than the rest.
We failed to demonstrate a worse prognosis for LVI and for
females in any of the outcomes. The incidence of LVI was very low
(under 5%) and, because its effects have been noted to correlate
with depth of LP invasion, it is unclear whether LVI independently
predicts outcome, or whether its detrimental impact is already
captured by pathologic information on substaging (Martin-Doyle
et al, 2014). Regarding gender, large population-based studies may
be required to confirm a worse prognosis of females that has been
suggested previously (Palou et al, 2012).
In summary, our report proposes a novel approach for HGT1
BC based on the selection of patients who will most benefit from a
second TUR, specifically those with deep invasion of the MM
(T1b). The main clinical implication of separately identifying
almost half of HGT1 cases with T1a substaging as having a low
(4%) progression rate is that they can be spared a second
endoscopic procedure with no harm. More accurate risk
stratification incorporating depth of invasion, associated CIS, and
tumour size would enable improved resource allocation for reTUR.
It would also help identify optimal candidates for prompt
cystectomy, namely T1b tumours larger than 3 cm and with
associated CIS. If the one in five HGT1 patients who will eventually
develop a muscle invasive BC could be identified after diagnostic
TUR, then cystectomy could be offered more selectively. Also,
overtreatment and the morbidity and anxiety of undergoing
additional procedures could be spared in patients with more
indolent prognosis. Our results further support the notion that the
‘rule of thirds for HGT1’ (i.e., one-third will never recur, one-third
will require deferred cystectomy, and one-third will die of disease)
is currently outdated.
Given the low impact of available scoring systems and biological
markers (van Rhijn et al, 2012), and in view of this data, depth of
invasion might be considered as the strongest prognostic factor for
progression in HGT1. In addition, recent evidence suggests that
histopathological classification into pTa, pT1a, and pT1b can be
translated into a molecular signature, reflecting progressive
dysregulation to more invasive stages (Descotes et al, 2013). Based
on the prognostic impact of T1 substaging in the present and
Table 4a. Univariate analysis for progression; association of substaging, tumour pattern, size and whether patients had CIS with
time to progression at 2 and 5 years (only showing variables with significant P-values)
N Prog
Progression free
at 2 years
Progression free
at 5 years
Hazard ratio and
95% CI P
Substaging 0.0004
T1a 89 5 0.95 (0.90, 0.99) 0.80 (0.71, 0.86) 0.21 (0.08, 0.54)
T1b 110 26 0.81 (0.72, 0.87) 0.74 (0.61, 0.83) 1 (reference)
Tumour pattern 0.006
Papillary 165 21 0.91 (0.85, 0.94) 0.87 (0.80, 0.92) 0.37 (0.17, 0.78)
Solid 34 10 0.73 (0.55, 0.85) 1 (reference)
Tumour size 0.04
o3 cm 113 12 0.91 (0.84, 0.95) 0.87 (0.75, 0.93) 0.59 (0.35, 0.99)
43 cm 86 19 0.83 (0.73, 0.90) 0.76 (0.64, 0.85) 1 (reference)
CIS o0.0001
Yes 56 18 0.71 (0.57, 0.81) 0.60 (0.39, 0.76) 1 (reference)
No 143 13 0.94 (0.89, 0.97) 0.90 (0.83, 0.95) 0.23 (0.11, 0.48)
Abbreviations: CI¼ confidence interval; CIS¼ carcinoma in situ. Po0.05 represent statistically significant values (shown in bold).
Table 4b. Multivariable analysis for progression; association
of significant variables in univariate analysis together with
lymphovascular invasion and gender were analysed
Hazard ratio and
95% CI P
Substaging (T1a) 0.30 (0.12, 0.81) 0.02
CIS (No) 0.24 (0.12, 0.81) 0.0002
Size (o3 cm) 0.41 (0.19, 0.87) 0.02
Pattern (papillary) 0.68 (0.31, 1.48) 0.33
Lymphovascular invasion (yes) 2.07 (0.60, 7.10) 0.25
Gender (male) 1.23 (0.37, 4.12) 0.74
Abbreviations: CI¼ confidence interval; CIS¼ carcinoma in situ. Po0.05 represent
statistically significant values (shown in bold).
Table 4c. Combined risk for the association of T1b, larger
tumour size and associated CIS
Hazard ratio and
95% CI P
Substaging (T1a) 0.25 (0.12, 0.52) 0.0002
CIS (no) 0.28 (0.11, 0.73) 0.009
Size (o3 cm) 0.40 (0.19, 0.84) 0.014
Abbreviations: CI¼ confidence interval; CIS¼ carcinoma in situ. Po0.05 represent
statistically significant values (shown in bold).
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previous studies, we believe there is an argument for evolution of
the current TNM classification. Together with tumour size and the
detection of CIS an updated classification would help to identify
the patients most suitable for cystectomy. Randomised control
trials to evaluate the positive impact of this subclassification of
tumours would also be beneficial.
CONCLUSIONS
With this contemporary approach for the management of HGT1
BC, in which the strategy of complete initial TURþMitCþBCG is
only followed by a second TUR in T1b cases, low recurrence and
progression rates (28.5% and 15.5%, respectively) are achieved.
Together with LP substaging (T1a vs T1b), tumour size and
associated CIS are also prognostic factors for progression, which
should be contemplated in future strategies and aid in the selection
of patients for cystectomy.
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